OnKure Therapeutics, Inc. Cash Flow Conversion Efficiency
OnKure Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.35 Million) by net assets ($172.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OnKure Therapeutics, Inc. (2020–2025)
Cash flow conversion efficiency of OnKure Therapeutics, Inc. from 2020 to 2025. This chart illustrates how OnKure Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View OKUR stock price and chart for real-time trading data and today's change.
OnKure Therapeutics, Inc. Cash Flow Conversion Ratio Explained
OnKure Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OnKure Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see OnKure Therapeutics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carnaby Resources Ltd
AU:CNB
|
-0.074x |
|
Social Commerce Partners Corporation Class A Ordinary Shares
NASDAQ:SCPQ
|
-0.001x |
|
Ctek AB
ST:CTEK
|
0.182x |
|
Honghua Group Limited
F:4HB
|
0.011x |
|
Min Aik Technology Co Ltd
TW:3060
|
-0.028x |
|
Sejong Industrial
KO:033530
|
0.053x |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
N/A |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
0.100x |
Annual Cash Flow Conversion Efficiency for OnKure Therapeutics, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of OnKure Therapeutics, Inc. from 2020 to 2025. Review free cash flow generation of OnKure Therapeutics, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.18 Million | $-51.83 Million | -0.922x | -87.37% |
| 2024-12-31 | $103.83 Million | $-51.12 Million | -0.492x | -245.14% |
| 2023-12-31 | $-101.84 Million | $-34.55 Million | 0.339x | -31.51% |
| 2022-12-31 | $-54.42 Million | $-26.95 Million | 0.495x | +291.96% |
| 2021-12-31 | $147.21 Million | $-37.98 Million | -0.258x | -158.62% |
| 2020-12-31 | $-42.12 Million | $-18.54 Million | 0.440x | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more